Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study highlights the diverse prescribing and monitoring practices for low-dose oral minoxidil among dermatologists in the UK and Ireland, used widely for various hair loss conditions both as monotherapy and adjunctive therapy.

Minoxidil reacts to nitrosation 7 times more than phenol, mainly due to its -NH₂ groups, leading to the creation of N-nitrosominoxidil.

This study investigated the potential of nutmeg-derived phytochemicals as anti-alopecia agents using molecular docking and simulations, finding that geranylgeraniol exhibited significant binding stability and potential efficacy against androgenetic alopecia comparable to finasteride and superior to minoxidil.

Low-dose oral minoxidil can cause dizziness in women without lowering blood pressure, so careful monitoring is needed.

In this study, maslinic acid applied topically was observed to stimulate hair growth in mice comparably to minoxidil, primarily activating pathways like Wnt/β-catenin, and suggesting a link between hair growth and cilia activity.

This study found that alpha mangostin protected wild-type MCF10A breast cancer cells, but not p53 knockout cells, from damage by the chemotherapy agent paclitaxel.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

This study identified a new minoxidil analogue called triaminodil in an illegal hair-growth supplement, but no data on its chemical, toxicological, or pharmacological properties are available yet.

This study found that cardamonin may inhibit OSCC cell migration, proliferation, and invasion by affecting the PI3K/AKT pathway, suggesting its potential as a treatment.

This study found that the extract of Eclipta prostrata L. demonstrated high antioxidant and anti-acetylcholinesterase activities, moderate inhibition of enzymes linked to diabetes, and favorable ADMET properties, suggesting potential cognitive and diabetes management benefits.

This study found that Avicennia marina extract and its active compound avicequinone C inhibit enzymes and receptors related to androgenic alopecia, potentially supporting hair growth in cultured dermal papilla cells.

This study found that Lophocereus marginatus extracts significantly inhibited melanoma cell growth in vitro and stimulated hair growth in mice, with combined treatments of LM with minoxidil or bergamot showing notable effects by day 14 without altering body weight.

This study reported that compound 16 (olean-12-en-3beta-ol, cinnamate) from Merremia peltata showed potential as an androgen receptor antagonist, suggesting it may benefit alopecia treatment based on molecular docking and ADME-Tox predictions.

This study found that a 2% topical minoxidil solution benefited 63% of men with androgenic alopecia by slowing balding or increasing hair density, but only 6.6% saw dramatic cosmetic improvement.

This review discusses two FDA-approved drugs for androgenetic alopecia, finasteride and minoxidil, and reports no new research findings.

This source suggests that oral minoxidil could be a safe and effective treatment option for both female and male androgenetic alopecia, although it is currently used off-label.

This study found that for people with androgenetic alopecia, increasing the dosage of low-dose oral minoxidil is associated with improvements in hair diameter and density, but also raises the risk of hypertrichosis and cardiovascular adverse events.

In a depilation mouse model, this study found that Limosilactobacillus fermentum MF10 promoted hair growth and increased follicle size by activating skin Wnt/β-catenin signaling and modulating gut microbiota, with effects comparable to the positive control finasteride.

Low-dose oral minoxidil effectively treats female hair loss with good safety.

This study found that the carbohydrate-based excipient β-cyclodextrin forms a stable inclusion complex with the active ingredient of Minoxicapil®, potentially enhancing its formulation for hair-loss treatment, and in vitro assays suggest improved proliferation of DPC cells, supporting its use in topical treatments.

This case study involving a 63-year-old woman with female pattern hair loss found that a 3-month regimen of low-dose oral minoxidil increased hair density from 98 to 140 hairs per square centimeter, but caution was advised regarding its safety and efficacy without larger trials.

This study investigated the effects of Christia vespertilionis extract on breast cancer cell lines, finding that it had a concentration-dependent cytotoxic effect, although less potent than tamoxifen, suggesting potential as an alternative cancer treatment.

This study found that low-dose oral minoxidil effectively increased hair count over 24 weeks with mild reductions in blood pressure and minimal adverse effects among participants, suggesting its potential as a safe treatment for hair loss.

This study found that Minoxidil included in triamino alpha-cyclodextrin significantly promoted hair growth in mice, potentially due to its enhanced substantivity on skin.

This study found that rapidly administered intravenous cimetidine may cause a significant drop in blood pressure in critically ill patients, whereas ranitidine does not appear to have the same effect.

This study found that humulen, a phytoconstituent of Cyperus Rotundus Linn., showed the highest binding affinity in molecular docking with the 5 α reductase enzyme, suggesting potential anti-androgenic effects for hirsutism treatment.

This article reflects on the history and significance of the FDA's approval of topical minoxidil for treating androgenetic alopecia in men and women, dating back to 1988 and 1991 respectively.

This review concluded that low-dose oral minoxidil is an effective and well-tolerated treatment for male androgenetic alopecia, with significant hair density improvements and manageable side effects.